Medical oncology (Northwood, London, England)
Dec 26, 2025
Adeno-associated virus (AAV) has emerged as a pivotal vector for cancer gene therapy due to its low immunogenicity, non-pathogenicity, and sustained transgene expression capacity. However, the heterogeneity and complexity of the tumor microenvironmen...
Journal of controlled release : official journal of the Controlled Release Society
Nov 27, 2025
Glioblastoma (GBM) is an aggressive central nervous system (CNS) malignancy with a poor prognosis and limited responses to conventional therapies. RNA-based therapeutics, with their gene-targeting specificity, present a promising avenue for GBM treat...
Microfluidic technologies have revolutionized the synthesis of nanocarriers for drug and gene delivery, providing unparalleled precision and efficiency in the production of therapeutic nanoparticles. This review highlights recent advancements in micr...
Lipid nanoparticles (LNPs) are a promising nonviral delivery system for gene-editing proteins, but optimal formulations remain underexplored. Unlike messenger RNA-based approaches, ribonucleoprotein delivery enables immediate genome editing without r...
Journal of controlled release : official journal of the Controlled Release Society
Aug 28, 2025
Adipose tissue plays a crucial role in energy metabolism and endocrine signaling. White adipose tissue (WAT), in particular, is a compelling target for therapeutic interventions in metabolic diseases due to its secretory capacity and abundance. Gene ...
Ocular gene therapy offers a promising approach for treating various eye diseases, centered on the process of transfection, including delivery, cellular uptake and gene expression. This study addresses anatomical and physiological barriers, such as t...
Critical reviews in oncology/hematology
Mar 13, 2025
The convergence of artificial intelligence (AI) and nanomedicine has revolutionized the design of smart multifunctional nanocarriers (SMNs) for drug and gene delivery, offering unprecedented precision, efficiency, and personalization in therapeutic a...
Journal of controlled release : official journal of the Controlled Release Society
Oct 28, 2024
There is a clinical need to develop lipid nanoparticles (LNPs) to deliver congenital therapies to the fetus during pregnancy. The aim of these therapies is to restore normal fetal development and prevent irreversible conditions after birth. As a firs...
Ionizable lipid nanoparticles (LNPs) are seeing widespread use in mRNA delivery, notably in SARS-CoV-2 mRNA vaccines. However, the expansion of mRNA therapies beyond COVID-19 is impeded by the absence of LNPs tailored for diverse cell types. In this ...
Cationic polymers offer an alternative to viral vectors in nucleic acid delivery. However, the development of polymer vehicles capable of high transfection efficiency and minimal toxicity has remained elusive, and continued exploration of the vast de...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.